HHMI: Bitterness Remains

WASHINGTON—Behind Donald Fredrickson's forced resignation June 2 as president and lifetime trustee of the Howard Hughes Medical Institute lies a tale of budget overruns and unorthodox purchasing procedures that HHMI trustees and officials say stem from his wife's active and inappropriate role at the institute. "It's big and it's bad," said HHMI chairman George Thorn about the results of the six-month review conducted by the New York law firm of Paul, Weiss, Rifkind, Wharton & Garrison, abo

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

"It's big and it's bad," said HHMI chairman George Thorn about the results of the six-month review conducted by the New York law firm of Paul, Weiss, Rifkind, Wharton & Garrison, about which he declined to provide details. Thorn is serving as acting chief executive officer while a search continues for a new president.

Fredrickson, a former NIH director, has a sharply different view of the events that led to his departure from the $5 billion institute that he had headed since 1984. An investigation into "rumors" that his wife, Henrietta, had too large a role in HHMI activities soon mushroomed into brutal personal questioning that made it "impossible [for me] to go back," he said.

Fredrickson acknowledges that one item that came under scrutiny is a $2.5 million cost overrun in a $12.5 million project to renovate the Cloisters, a former convent on the NIH campus being converted into ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Ron Cowen

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio